Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience

Am J Hematol. 2022 Jul;97(7):E276-E280. doi: 10.1002/ajh.26580. Epub 2022 May 2.

Authors

Meera Mohan¹, Melody Renee Becnel², Urvi A Shah³, Huaying Dong¹, Sravani Gundarlapalli⁴, Timothy Peterson⁵, Jennifer S Orozco⁵, Sandra Horowitz², Saurabh Chhabra¹, Binod Dhakal¹, Sharmilan Thanendrarajan⁴, Sabarinath Venniyil Radhakrishnan¹, Samer Al Hadidi⁴, Carlyn Tan³, Sham Mailankody³, Malin Hultcrantz³, Neha Korde³, Hani Hassoun³, Alexander M Lesokhin³, Sheeba K Thomas², Krina K Patel², Elisabet E Manasanch², Donna M Weber², Aniko Szabo¹, Gregory P Kaufman², Hans C Lee², Maurizio Zangari⁴, Frits van Rhee⁴, Saad Z Usmani³, Anita D'Souza¹, Robert Z Orlowski², Carolina Schinke⁴

Affiliations

¹ Medical College of Wisconsin, Froedtert Clinical Cancer Center, Division of Hematology/Oncology, Milwaukee, Wisconsin, USA.
² The University of Texas MD Anderson Cancer Center, Department of Lymphoma & Myeloma, Houston, Texas, USA.
³ Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
⁴ Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
⁵ Janssen Pharmaceuticals, Beerse, Belgium.

No abstract available

Publication types

Letter
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

ADP-ribosyl Cyclase 1
Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents, Immunological* / therapeutic use
Humans
Multiple Myeloma* / drug therapy
Multiple Myeloma* / genetics
Treatment Outcome

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
ADP-ribosyl Cyclase 1

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States